2012
DOI: 10.1016/j.ejmech.2012.06.050
|View full text |Cite
|
Sign up to set email alerts
|

N-Aryl-N′-(chroman-4-yl)ureas and thioureas display in vitro anticancer activity and selectivity on apoptosis-resistant glioblastoma cells: Screening, synthesis of simplified derivatives, and structure–activity relationship analysis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
11
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
8
1

Relationship

2
7

Authors

Journals

citations
Cited by 30 publications
(14 citation statements)
references
References 41 publications
1
11
0
Order By: Relevance
“…The presence of the tetramethylchromanol skeleton in compound MK61 is probably related with its strongest activity. This is also in agreement with other reports that describe the high antitumor activity of compounds with this skeleton in their structure . On the other hand, the antitumor activity showed by compounds MK149 and MK150 seems to be related with the presence of 1,2‐dimethoxyphenyl pharmacophores.…”
Section: Resultssupporting
confidence: 93%
“…The presence of the tetramethylchromanol skeleton in compound MK61 is probably related with its strongest activity. This is also in agreement with other reports that describe the high antitumor activity of compounds with this skeleton in their structure . On the other hand, the antitumor activity showed by compounds MK149 and MK150 seems to be related with the presence of 1,2‐dimethoxyphenyl pharmacophores.…”
Section: Resultssupporting
confidence: 93%
“…Therefore, we hypothesized that induction of apoptosis should not be the primary mechanism of action of these compounds that could thus be used to combat models associated with, at least partial, intrinsic resistance to pro-apoptotic stimuli. If at first glance, DBHB appeared to have rather weak activity (at least in terms of IC 50 in vitro growth inhibitory concentrations), it must kept in mind that temozolomide, the most efficacious drug used clinically to treat glioblastoma [23], has IC 50 in vitro growth inhibitory concentrations ranging between 220 (U373) and 956 (Hs683) µM, depending on the glioma cell line [37]. The same features were observed for another widely used compound to combat various cancer types, i.e.…”
Section: Resultsmentioning
confidence: 99%
“…Urea was the selected linker to replace ester function in CAPE because urea moiety contains both hydrogen bond donors and hydrogen bond acceptors, so it is prone to the formation of hydrogen bond. Several modified urea derivatives demonstrated diverse array of anti-proliferative properties (Li et al, 2010;Guagnano et al, 2011;Goffin et al, 2012;Defaux et al, 2014) e.g. sorafenib.…”
Section: Chemistrymentioning
confidence: 98%